Beam Therapeutics Stock Income Statements

Beam Therapeutics Quarterly Income Statements Chart

Quarterly

Annual

Operating Profit

Net Income

Beam Therapeutics Quarterly Income Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31

license and collaboration revenue	8,466,000	7,470,000	30,067,000	14,269,000	11,772,000	7,410,000	316,192,000	17,193,000	20,116,000	24,208,000	20,037,000	15,799,000	16,652,000	8,432,000	51,069,000	763,000
operating expenses:
research and development	101,758,000	98,816,000	101,444,000	94,258,000	87,041,000	84,818,000	140,077,000	100,050,000	97,608,000	99,646,000	86,341,000	85,287,000	74,556,000	65,410,000	96,781,000	54,623,000	45,577,000	190,106,000	32,451,000	29,825,000	19,354,000	21,549,000
general and administrative	26,859,000	27,940,000	28,660,000	26,515,000	29,626,000	26,724,000	43,257,000	25,410,000	24,656,000	23,490,000	22,681,000	21,815,000	24,062,000	19,247,000	17,772,000	15,774,000	13,403,000	10,273,000	8,354,000	7,502,000	6,937,000	6,812,000
total operating expenses	128,617,000	126,756,000	130,104,000	120,773,000	116,667,000	111,542,000	183,334,000	125,460,000	122,264,000	123,136,000	109,022,000	107,102,000	98,618,000	84,657,000	114,553,000	70,397,000	58,980,000	200,379,000	40,805,000	37,327,000	26,291,000	28,361,000
income from operations	-120,151,000	-119,286,000	-100,037,000	-106,504,000	-104,895,000	-104,132,000	132,858,000	-108,267,000	-102,148,000	-98,928,000	-88,985,000	-91,303,000	-81,966,000	-76,225,000	-63,484,000	-69,634,000	-58,974,000	-200,373,000	-40,799,000	-37,321,000	-26,285,000	-28,355,000
yoy	14.54%	14.55%	-175.30%	-1.63%	2.69%	5.26%	-249.30%	18.58%	24.62%	29.78%	40.17%	31.12%	38.99%	-61.96%	55.60%	86.58%	124.36%	606.66%
qoq	0.73%	19.24%	-6.07%	1.53%	0.73%	-178.38%	-222.71%	5.99%	3.25%	11.17%	-2.54%	11.39%	7.53%	20.07%	-8.83%	18.08%	-70.57%	391.12%	9.32%	41.99%	-7.30%
operating margin %
other income:
change in fair value of derivative liabilities	1,147,000	2,260,000	-128,000	-200,000	5,500,000	-2,900,000	-1,900,000	4,700,000	-900,000	5,600,000	3,000,000	-4,900,000	12,200,000	13,600,000	7,400,000	35,800,000	-42,300,000	-1,900,000	-54,700,000	2,700,000	-8,700,000	-2,700,000
change in fair value of non-controlling equity investments	4,415,000	-2,081,000	-1,090,000	-2,064,000	-7,586,000	-3,353,000	-722,000	-11,221,000	6,148,000	-12,797,000	21,578,000	10,431,000	-4,124,000	-7,685,000
change in fair value of contingent consideration liabilities	-28,000	-27,000	-27,000	-27,000	1,779,000	-133,000	1,863,000	6,002,000	2,171,000	-296,000	19,447,000	-875,000	-120,000	452,000	-4,407,000	10,599,000	-741,000	-305,000
interest and other income	12,326,000	9,864,000	10,928,000	12,127,000	14,190,000	11,849,000	12,064,000	12,698,000	11,953,000	9,961,000	7,611,000	4,982,000	2,060,000	644,000	54,000	9,000	-52,000	1,018,000	35,000	169,000	767,000	597,000
total other income	17,860,000	10,016,000	9,683,000	9,836,000	13,883,000	5,463,000	11,305,000	12,179,000	19,372,000	2,468,000	51,636,000	9,638,000	10,016,000	7,011,000	-1,223,000	41,516,000	-17,279,000	-1,187,000	-54,665,000	2,869,000	-7,933,000	-2,103,000
net income before income taxes	-102,291,000		-90,354,000	-96,668,000	-91,012,000		144,163,000	-96,088,000			-37,349,000	-81,665,000
benefit from income taxes					-39,000						-1,000,000	-2,410,000
net income	-102,291,000	-109,270,000	-90,354,000	-96,668,000	-91,051,000	-98,669,000	142,797,000	-96,088,000	-82,776,000	-96,460,000	-38,349,000	-109,575,000	-71,950,000	-69,214,000	-64,707,000	-28,118,000	-76,253,000	-201,560,000	-95,464,000	-34,452,000	-34,218,000	-30,458,000
yoy	12.34%	10.74%	-163.27%	0.60%	10.00%	2.29%	-472.36%	-12.31%	15.05%	39.36%	-40.73%	289.70%	-5.64%	-65.66%	-32.22%	-18.38%	122.84%	561.76%
qoq	-6.39%	20.94%	-6.53%	6.17%	-7.72%	-169.10%	-248.61%	16.08%	-14.19%	151.53%	-65.00%	52.29%	3.95%	6.97%	130.13%	-63.13%	-62.17%	111.14%	177.09%	0.68%	12.34%
net income margin %
unrealized gain on marketable securities	-150,000	-519,000	-1,080,000	2,869,000	-189,000	-1,525,000	2,628,000	-9,000	-1,250,000	1,665,000	2,244,000	-484,000	-1,481,000	-2,659,000	-69,000	-12,000	55,000		-50,000	-132,000	517,000
comprehensive loss	-102,441,000	-109,789,000	-91,434,000	-93,799,000	-91,240,000	-100,194,000	145,425,000	-96,097,000	-84,026,000	-94,795,000	-36,105,000	-110,059,000	-73,431,000	-71,873,000	-64,776,000	-28,130,000	-76,198,000	-201,575,000	-95,514,000	-34,584,000	-33,701,000	-30,818,000
net income per common share, basic and diluted	-1,000	-1,240	-1,090	-1,170	-1,110	-1,210	1,910	-1,220	-1,080	-1,330	-897.5	-1,560	-1,020	-1,010
weighted-average common shares outstanding, basic and diluted	101,995,184,000	87,975,311,000	82,313,008,000	82,410,095,000	82,312,467,000	81,698,633,000	77,151,771,000	79,024,647,000	76,335,175,000	72,273,829,000	70,015,305,000	70,343,196,000	70,210,227,000	68,703,864,000
income from equity method investment												-25,500,000
change in fair value of long-term investments															5,490,000	-4,892,000	25,814,000
reconciliation of net income to net income attributable to common stockholders:
accretion of redeemable convertible preferred stock to redemption value, including dividends on preferred stock																						-1,277,000
net income attributable to common stockholders															-64,707,000	-28,118,000	-76,253,000	-201,560,000	-95,464,000	-34,452,000	-34,218,000	-31,735,000
net income per common share attributable to common stockholders, basic and diluted															-910	-420	-1,230	-3,350	-1,880	-690	-690	-1,030
weighted-average common shares used in net income per share attributable to common stockholders, basic and diluted															64,227,676	66,377,611	62,210,239	60,210,120	46,733,221	50,087,747	49,430,138	30,725,077
license revenue																	6,000	6,000	6,000	6,000	6,000	6,000
unrealized loss on marketable securities																		-15,000				-360,000

We provide you with 20 years income statements for Beam Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Beam Therapeutics stock. Explore the full financial landscape of Beam Therapeutics stock with our expertly curated income statements.

The information provided in this report about Beam Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.